Colgate-Palmolive holder plans 15,000-share Rule 144 sale

Colgate-Palmolive common stock holder plans Rule 144 sale of 15,000 shares of common stock through Merrill Lynch on the NYSE, with an aggregate market value of 1,467,111.44.

Rhea-AI Filing Summary

Colgate-Palmolive common stock holder plans Rule 144 sale of 15,000 shares of common stock through Merrill Lynch on the NYSE, with an aggregate market value of 1,467,111.44. The issuer reports 806,064,942 common shares outstanding.

The 15,000 shares were acquired on 02/12/2026 via an exercise of employee stock options in a broker-assisted cashless exercise, with payment also on 02/12/2026. The filing also lists a prior sale of 35,000 common shares on 02/11/2026 by Panagiotis Tsourapas for gross proceeds of 3,311,325.24.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is disclosed in Colgate-Palmolive (CL) Rule 144 filing?

The notice covers a planned sale of 15,000 shares of Colgate-Palmolive common stock through Merrill Lynch on the NYSE, with an aggregate market value of $1,467,111.44. It is filed under Rule 144 for restricted or control securities.

How were the 15,000 Colgate-Palmolive (CL) shares acquired under Rule 144?

The 15,000 Colgate-Palmolive shares were acquired on February 12, 2026 through an exercise of employee stock options. The transaction used a broker-assisted cashless exercise, with the acquisition date and payment date both listed as 02/12/2026.

Which broker and exchange are involved in this Colgate-Palmolive (CL) stock sale?

The planned Rule 144 sale uses Merrill Lynch at 225 Liberty Street, New York, as broker. The 15,000 Colgate-Palmolive common shares are expected to be sold on the New York Stock Exchange (NYSE), as specified in the filing’s securities information table.

What recent Colgate-Palmolive (CL) stock sales are reported for the past 3 months?

The filing lists a prior sale by Panagiotis Tsourapas of 35,000 Colgate-Palmolive common shares on 02/11/2026, generating $3,311,325.24 in gross proceeds. This is disclosed as part of securities sold during the past three months.

How many Colgate-Palmolive (CL) shares are outstanding according to this filing?

The Rule 144 notice states that 806,064,942 shares of Colgate-Palmolive common stock are outstanding. This provides context for the planned sale of 15,000 shares, showing the relative size of the proposed transaction versus total shares.

What representation does the seller make in this Colgate-Palmolive (CL) Rule 144 notice?

By signing the notice, the selling person represents that they do not know any material adverse information about Colgate-Palmolive’s current or prospective operations that has not been publicly disclosed, as required in connection with Rule 144 sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001576945
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	COLGATE PALMOLIVE CO
SEC File Number	001-00644
Address of Issuer	300 PARK AVE NEW YORK NEW YORK 10022
Phone	2123102000
Name of Person for Whose Account the Securities are To Be Sold	Tsourapas Panagiotis
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	15000	1467111.44	806064942	02/12/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/12/2026	Exercise of employee stock options	COLGATE PALMOLIVE CO			15000	02/12/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Panagiotis Tsourapas 300 PARK AVE NEW YORK NY 10022	Common Stock	02/11/2026	35000	3311325.24

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Panogiotis Tsourapas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)